Efficacy of Proton Pump Inhibitors in GERD Grades A to D: Symptom Relief and Endoscopic Healing Outcomes.

Abstract

Background: Gastroesophageal reflux disease (GERD) is a common condition managed primarily with proton pump inhibitors (PPIs). However, the therapeutic response may vary with disease severity.

Objective: To evaluate the effectiveness of standard-dose PPI therapy across GERD grades A to D in terms of symptom relief and endoscopic healing.

Study Design : A Prospective observational Study.

Place and Duration of study . Department Of Gastroenterology MTI, Lady Reading Hospital Peshawar Pakistan from jan 2023 to dec 2023

Methods: This prospective observational study enrolled 120 patients diagnosed with GERD based on clinical and endoscopic criteria. Patients received omeprazole 40 mg once daily for 8 weeks. Symptom scoring (GERD-Q) and endoscopic grading (LA classification) were conducted before and after treatment. Outcomes were analyzed using chi-square testing.

Results: Symptom relief was observed in 93.3% (Grade A), 86.8% (Grade B), 72.4% (Grade C), and 52.2% (Grade D) (p = 0.0015). Endoscopic healing occurred in 90.0% (Grade A), 81.6% (Grade B), 65.5% (Grade C), and 39.1% (Grade D) (p = 0.00023).

Conclusion: PPIs are highly effective in Grades A and B but significantly less so in Grades C and D. Individualized treatment strategies should be based on GERD severity